Randomized, Double-blind, Safety and Efficacy of Recombinant Human Erythropoietin in Amyotrophic Lateral Sclerosis

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 20, 2016

Primary Completion Date

December 31, 2020

Study Completion Date

December 31, 2025

Conditions

Amyotrophic Lateral Sclerosis

Interventions

DRUG

recombinant human erythropoietin(rhEPO)

Injection of erythropoietin every months (total 12 months)

Trial Locations (1)

RECRUITING

Hanyang Medical Center, Seoul

All Listed Sponsors

lead

Hanyang University Seoul Hospital

OTHER